Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1994 Feb;85(2):187–193. doi: 10.1111/j.1349-7006.1994.tb02081.x

Different Modes of Cell‐killing Action between DNA Topoisomerase I and II Inhibitors Revealed by Kinetic Analysis

Makoto Inaba 1,✉, Junko Mitsuhashi 1, Shouzou Kawada 2, Hirofumi Nakano 2
PMCID: PMC5919418  PMID: 8144400

Abstract

We compared the modes of cell‐killing by DNA topoisomerase I and II inhibitors. The effects of camptothecin (CPT), KT‐6528 and UCE6 upon colony formation by inhibiting DNA topoisomerase I, and of etoposide (VF‐16), teniposide, amsacrine and UCT4‐A as inhibitors of DNA topoisomerase II were analyzed based upon a kinetic method that distinguishes between cell cycle phase‐specific and ‐nonspecific agents. Human colorectal cancer WiDr cells were exposed to several concentrations of each agent for various periods and 90%‐inhibitory concentrations (IC90) at each time were determined by means of a clonogenic assay. When exposure times and corresponding IC90s were plotted on a log‐log scale, all inhibitors of DNA topoisomerase II gave curves including a linear portion with a slope of −1, which is characteristic of cell cycle phase‐nonspecific agents. In contrast, the curves for all inhibitors of DNA topoisomerase I had a much steeper slope than −1, which is typical of cell cycle phase‐specific agents. In agreement with this finding, the cells were remarkably accumulated in the G2‐M phase when exposed to VP‐16, but in late S‐phase when exposed to CPT as determined by a flow cytometric assay. These results indicated that the two classes of agents kill cells in a quite different manner although they are inhibitors of similar enzymes.

Keywords: DNA topoisomerase inhibitor, Camptothecin, Etoposide, Cell killing action, Kinetic analysis

Full Text

The Full Text of this article is available as a PDF (359.3 KB).

REFERENCES

  • 1. ) Liu , L. F.DNA topoisomerase poisons as antitumor drugs . Annu. Rev. Biochem. , 58 , 351 – 375 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Pommier , Y.DNA topoisomerase I and II in cancer chemotherapy: update and perspectives . Cancer Chemother. Pharmacol. , 32 , 103 – 108 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Zhang , H. , D'Arpa , P. and Liu , L. F.A model for tumor cell killing by topoisomerase poisons . Cancer Cells , 2 , 23 – 27 ( 1990. ). [PubMed] [Google Scholar]
  • 4. ) Gewirtz , D. A.Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors ? Biochem. Pharmacol. , 42 , 2253 – 2258 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Hsiang , Y.‐H. , Lihou , M. G. and Liu , L. F.Arrest of replication forks by drug‐stabilized topoisomerase I‐DNA cleavable complexes as a mechanism of cell killing by camptothecin . Cancer Res. , 49 , 5077 – 5082 ( 1989. ). [PubMed] [Google Scholar]
  • 6. ) D'Arpa , P. , Beardmore , C. and Liu , L. F.Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons . Cancer Res. , 50 , 6919 – 6924 ( 1990. ). [PubMed] [Google Scholar]
  • 7. ) Chow , K.‐C. , King , C. K. and Ross , W. E.Abrogation of etoposide‐mediated cytotoxicity by cycloheximide . Biochem. Pharmacol. , 37 , 1117 – 1122 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Holm , C. , Covey , J. M. , Kerrigan , D. and Pommier , Y.Differential requirement of DNA replication of cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells . Cancer Res. , 49 , 6365 – 6368 ( 1989. ). [PubMed] [Google Scholar]
  • 9. ) Schneider , E. , Lawson , P. A. and Ralph , R. K.Inhibition of protein synthesis reduces the cytotoxicity of 4′‐(9‐acridinylamino)methanesulfon‐m‐anisidide without affecting DNA breakage and DNA topoisomerase II in a murinemastocytoma cell line . Biochem. Pharmacol. , 38 , 263 – 269 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Ozawa , S. , Sugiyama , Y. , Mitsuhashi , Y. , Kobayashi , T. and Inaba , M.Cell killing action of cell cycle phase non‐specific antitumor agents is dependent on concentration‐time product . Cancer Chemother. Pharmacol. , 21 , 185 – 190 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Ozawa , S. , Sugiyama , Y. , Mitsuhashi , J. and Inaba , M.Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells . Cancer Res. , 49 , 3823 – 3828 ( 1989. ). [PubMed] [Google Scholar]
  • 12. ) Inaba , M. , Mitsuhashi , J. and Ozawa , S.Kinetic analysis of 5‐fluorouracil action against various cancer cells . Jpn. J. Cancer Res. , 81 , 1039 – 1044 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. ) Yamashita , Y. , Fujii , N. , Murakata , C. , Ashizawa , T. , Okabe , M. and Nakano , H.Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives . Biochemistry , 31 , 12069 – 12075 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Fujii , N. , Yamashita , Y. , Chiba , S. , Uosaki , Y. , Saitoh , Y. , Tuji , Y. and Nakano , H.UCE6, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from actinomycetes . J. Antibiot. , 46 , 1173 – 1174 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Kawada , S. , Yamashita , Y. , Fujii , N. and Nakano , H.Induction of a heat‐stable topoisomerase II‐DNA cleavable complex by nonintercalative terpenoids, terpentecin and clerocidin . Cancer Res. , 51 , 2922 – 2925 ( 1991. ). [PubMed] [Google Scholar]
  • 16. ) Heck , M. N. M. , Hittelman , W. N. and Earnshaw , W. C.Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle . Proc. Natl. Acad. Sci. USA , 85 , 1086 – 1090 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. ) Hsiang , Y.‐H. , Wu , H.‐Y. and Liu , L. F.Proliferation‐dependent regulation of DNA topoisomerase II in cultured human cells . Cancer Res. , 48 , 3230 – 3235 ( 1988. ). [PubMed] [Google Scholar]
  • 18. ) Bertrand , R. , Kerrigan , D. , Sarang , M. , and Pommier , Y.Cell death induced by topoisomerase inhibitors: role of calcium in mammalian cells . Biochem. Pharmacol. , 42 , 77 – 85 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Tanabe , K. , Ikegami , Y. , Ishida , R. and Andoh , T.Inhibition of topoisomerase II by antitumor agents bis(2,6‐dioxopiperazine) derivatives . Cancer Res. , 51 , 4903 – 4908 ( 1991. ). [PubMed] [Google Scholar]
  • 20. ) Ishida , R. , Miki , T. , Narita , T. , Yui , R. , Sato , M. , Utsumi , K. R. , Tanabe , K. and Andoh , T.Inhibition of intracellular topoisomerase II by antitumor bis(2,6‐dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex‐forming type inhibitors . Cancer Res. , 51 , 4909 – 4916 ( 1991. ). [PubMed] [Google Scholar]
  • 21. ) Narita , T. , Koide , Y. , Yaguchi , S. , Kimura , S. , Izumisawa , Y. , Takase , M. , Inaba , M. and Tsukagoshi , S.Antitumor activities and schedule dependence of orally administered MST‐16, a novel derivative of bis(2,6‐dioxopiperazine) . Cancer Chemother. Pharmacol. , 28 , 235 – 240 ( 1991. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES